C9354
Monoclonal Anti-COX II antibody produced in mouse
clone AS66, purified immunoglobulin, buffered aqueous solution
Synonym(s):
Anti-Cyclooxygenase II
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
MDL number:
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
AS66, monoclonal
form
buffered aqueous solution
species reactivity
human
technique(s)
flow cytometry: 1 μg/test, indirect ELISA: suitable, microarray: suitable, western blot: suitable
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... PTGS2(5743)
General description
COX-II is an isoform of COX enzyme with 604 amino acid residues that catalyzes the conversion of arachinodate to prostaglandin H2.
Immunogen
recombinant full length human COX II, 604 amino acids.
Application
Monoclonal Anti-COX II antibody produced in mouse is suitable for immunoblotting at a working concentration of 1 to 5 μg/mL, indirect ELISA, microarray and flow cytometry at 1 μg/test.
Biochem/physiol Actions
COX-II is a target of NSAID (non-steroidal anti-inflammatory drugs) such as aspirin. It is induced in migratory cells responding to pro-inflammatory stimuli and is an important mediator of inflammation. The prostaglandins produced by COX-II are responsible for the pain and swelling from inflammation. As this enzyme is involved in the production of inflammatory agents, it is the target of intense research and drug discovery activities. COX-II is expressed in new angiogenic endothelial cells, synoviocytes from rheumatoid arthritis patients. It is also markedly expressed in 85% to 90% of human colorectal adenocarcinomas.
Physical form
Solution in phosphate buffered saline, pH 7.4, containing 0.08% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Datasheet
R N Dubois
Alimentary pharmacology & therapeutics, 14 Suppl 1, 64-67 (2000-05-12)
Use of nonsteroidal anti-inflammatory drugs such as aspirin, which are known to inhibit cyclooxygenase activity, reduces the relative risk of colorectal cancer in humans by 40-50%. Animal and human studies have shown a 50-80% reduction in tumour multiplicity following treatment
J Adams et al.
Journal of neurochemistry, 66(1), 6-13 (1996-01-01)
We have characterised the induction of the mitogen-inducible form of cyclooxygenase, COX-2, in the rat cerebral cortex in response to excitotoxin injection into the nucleus basalis. This model is associated with intense stimulation of the ascending pathway to the cerebral
G P O'Neill et al.
Molecular pharmacology, 45(2), 245-254 (1994-02-01)
Human prostaglandin G/H synthase (hPGHS)-1 and hPGHS-2, key enzymes in the formation of prostanoids from arachidonic acid, were expressed at high levels in COS-7 cells using a T7 RNA polymerase/vaccinia virus expression system. The open reading frame of hPGHS-2 cloned